Toxicity associated with high dosage 9-[(2R, 5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine therapy and attempts to abort early FIV infection

Katrin Hartmann, Gertrud Ferk, Thomas W. North, Niels C Pedersen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine, or D4API, was tested in the feline immunodeficiency virus (FIV) infection model and found to be significantly more inhibitory in vitro than its parent compound 9-phosphonylmethoxethyl adenine (PMEA). Cytotoxicity was less than for PMEA or azidothymidine (AZT) for culture periods of 7 days, but more toxic after 10 days. D4API was rapidly absorbed by cats following subcutaneous inoculation, with a plasma half-life of less than 1 h after intravenous inoculation and between 2 and 3 h after subcutaneous injection. Peripheral blood mononuclear cells collected from cats given a single dose of D4API were refractory, however, to FIV infection in vitro for up to 24 h. Given its prolonged intracellular phase and high selectivity index, high dose D4API therapy was tested for its ability to abort an acute (i.e. 2 week) FIV infection. A divided daily dose of D4API, which was one-fourth the toxic dose and 125 times the concentration that would totally inhibit virus replication in vitro, completely abrogated the anticipated viremia and antibody responses. Unfortunately, a majority of treated/uninfected and treated/infected test cats died acutely of drug toxicity after 47 days of treatment. Toxicity in vivo mirrored what was observed in vitro, being precipitous and cumulative in nature. Toxic signs included widespread hepatic and lymphoid necrosis. A surviving treated/FIV infected cat remained healthy to day 175 when the study was terminated; antibodies appeared 2 months later than in untreated/infected cats and virus was only detectable at low levels on day 175. In contrast, untreated/infected cats were viremic and antibody positive from 3 to 4 weeks post-infection onwards. Therefore, it was possible to alter, but not abort, an early FIV infection with prolonged, high-dose D4API treatment.

Original languageEnglish (US)
Pages (from-to)11-25
Number of pages15
JournalAntiviral Research
Volume36
Issue number1
DOIs
StatePublished - Oct 1997

Fingerprint

Feline Immunodeficiency Virus
Adenine
Virus Diseases
Cats
Poisons
Therapeutics
Zidovudine
Antibodies
Viremia
Subcutaneous Injections
Virus Replication
Drug-Related Side Effects and Adverse Reactions
Antibody Formation
Half-Life
Blood Cells
Necrosis
Viruses
In Vitro Techniques
Liver
Infection

Keywords

  • 9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine
  • Antiviral toxicity
  • Feline immunodeficiency virus

ASJC Scopus subject areas

  • Virology
  • Pharmacology

Cite this

Toxicity associated with high dosage 9-[(2R, 5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine therapy and attempts to abort early FIV infection. / Hartmann, Katrin; Ferk, Gertrud; North, Thomas W.; Pedersen, Niels C.

In: Antiviral Research, Vol. 36, No. 1, 10.1997, p. 11-25.

Research output: Contribution to journalArticle

@article{69b4192b9c6944edbbba774cb0f93f19,
title = "Toxicity associated with high dosage 9-[(2R, 5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine therapy and attempts to abort early FIV infection",
abstract = "9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine, or D4API, was tested in the feline immunodeficiency virus (FIV) infection model and found to be significantly more inhibitory in vitro than its parent compound 9-phosphonylmethoxethyl adenine (PMEA). Cytotoxicity was less than for PMEA or azidothymidine (AZT) for culture periods of 7 days, but more toxic after 10 days. D4API was rapidly absorbed by cats following subcutaneous inoculation, with a plasma half-life of less than 1 h after intravenous inoculation and between 2 and 3 h after subcutaneous injection. Peripheral blood mononuclear cells collected from cats given a single dose of D4API were refractory, however, to FIV infection in vitro for up to 24 h. Given its prolonged intracellular phase and high selectivity index, high dose D4API therapy was tested for its ability to abort an acute (i.e. 2 week) FIV infection. A divided daily dose of D4API, which was one-fourth the toxic dose and 125 times the concentration that would totally inhibit virus replication in vitro, completely abrogated the anticipated viremia and antibody responses. Unfortunately, a majority of treated/uninfected and treated/infected test cats died acutely of drug toxicity after 47 days of treatment. Toxicity in vivo mirrored what was observed in vitro, being precipitous and cumulative in nature. Toxic signs included widespread hepatic and lymphoid necrosis. A surviving treated/FIV infected cat remained healthy to day 175 when the study was terminated; antibodies appeared 2 months later than in untreated/infected cats and virus was only detectable at low levels on day 175. In contrast, untreated/infected cats were viremic and antibody positive from 3 to 4 weeks post-infection onwards. Therefore, it was possible to alter, but not abort, an early FIV infection with prolonged, high-dose D4API treatment.",
keywords = "9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine, Antiviral toxicity, Feline immunodeficiency virus",
author = "Katrin Hartmann and Gertrud Ferk and North, {Thomas W.} and Pedersen, {Niels C}",
year = "1997",
month = "10",
doi = "10.1016/S0166-3542(97)00030-2",
language = "English (US)",
volume = "36",
pages = "11--25",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Toxicity associated with high dosage 9-[(2R, 5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine therapy and attempts to abort early FIV infection

AU - Hartmann, Katrin

AU - Ferk, Gertrud

AU - North, Thomas W.

AU - Pedersen, Niels C

PY - 1997/10

Y1 - 1997/10

N2 - 9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine, or D4API, was tested in the feline immunodeficiency virus (FIV) infection model and found to be significantly more inhibitory in vitro than its parent compound 9-phosphonylmethoxethyl adenine (PMEA). Cytotoxicity was less than for PMEA or azidothymidine (AZT) for culture periods of 7 days, but more toxic after 10 days. D4API was rapidly absorbed by cats following subcutaneous inoculation, with a plasma half-life of less than 1 h after intravenous inoculation and between 2 and 3 h after subcutaneous injection. Peripheral blood mononuclear cells collected from cats given a single dose of D4API were refractory, however, to FIV infection in vitro for up to 24 h. Given its prolonged intracellular phase and high selectivity index, high dose D4API therapy was tested for its ability to abort an acute (i.e. 2 week) FIV infection. A divided daily dose of D4API, which was one-fourth the toxic dose and 125 times the concentration that would totally inhibit virus replication in vitro, completely abrogated the anticipated viremia and antibody responses. Unfortunately, a majority of treated/uninfected and treated/infected test cats died acutely of drug toxicity after 47 days of treatment. Toxicity in vivo mirrored what was observed in vitro, being precipitous and cumulative in nature. Toxic signs included widespread hepatic and lymphoid necrosis. A surviving treated/FIV infected cat remained healthy to day 175 when the study was terminated; antibodies appeared 2 months later than in untreated/infected cats and virus was only detectable at low levels on day 175. In contrast, untreated/infected cats were viremic and antibody positive from 3 to 4 weeks post-infection onwards. Therefore, it was possible to alter, but not abort, an early FIV infection with prolonged, high-dose D4API treatment.

AB - 9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine, or D4API, was tested in the feline immunodeficiency virus (FIV) infection model and found to be significantly more inhibitory in vitro than its parent compound 9-phosphonylmethoxethyl adenine (PMEA). Cytotoxicity was less than for PMEA or azidothymidine (AZT) for culture periods of 7 days, but more toxic after 10 days. D4API was rapidly absorbed by cats following subcutaneous inoculation, with a plasma half-life of less than 1 h after intravenous inoculation and between 2 and 3 h after subcutaneous injection. Peripheral blood mononuclear cells collected from cats given a single dose of D4API were refractory, however, to FIV infection in vitro for up to 24 h. Given its prolonged intracellular phase and high selectivity index, high dose D4API therapy was tested for its ability to abort an acute (i.e. 2 week) FIV infection. A divided daily dose of D4API, which was one-fourth the toxic dose and 125 times the concentration that would totally inhibit virus replication in vitro, completely abrogated the anticipated viremia and antibody responses. Unfortunately, a majority of treated/uninfected and treated/infected test cats died acutely of drug toxicity after 47 days of treatment. Toxicity in vivo mirrored what was observed in vitro, being precipitous and cumulative in nature. Toxic signs included widespread hepatic and lymphoid necrosis. A surviving treated/FIV infected cat remained healthy to day 175 when the study was terminated; antibodies appeared 2 months later than in untreated/infected cats and virus was only detectable at low levels on day 175. In contrast, untreated/infected cats were viremic and antibody positive from 3 to 4 weeks post-infection onwards. Therefore, it was possible to alter, but not abort, an early FIV infection with prolonged, high-dose D4API treatment.

KW - 9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine

KW - Antiviral toxicity

KW - Feline immunodeficiency virus

UR - http://www.scopus.com/inward/record.url?scp=0030824066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030824066&partnerID=8YFLogxK

U2 - 10.1016/S0166-3542(97)00030-2

DO - 10.1016/S0166-3542(97)00030-2

M3 - Article

VL - 36

SP - 11

EP - 25

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

IS - 1

ER -